tirzepatide farmacia benavides Mounjaro 2.5mg/0.6mL KwikPen 2.4 mL retatrutide clinical trial safety data

Da Silva, R

Tirzepatide's simultaneous targeting of both GLP-1 and GIP receptors is a unique feature that makes it a potent medicine for diabetes and weight loss

However, although the data obtained from preclinical studies involving a relatively small number of healthy subjects are promising, further comparative trials in larger populations of people with T2DM and obesity are required to confirm the therapeutic potential of this new GLP-1, GIP, and GCG receptor tri-agonist, particularly in comparison with existing selective GLP-1 and dual GLP-1/GIP receptor agonists

This medication slows the heart rate and increases the amount of blood moved with each heartbeat